Cooke & Bieler LP Purchases 126,372 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Cooke & Bieler LP lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 42.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 426,767 shares of the medical research company's stock after acquiring an additional 126,372 shares during the period. Cooke & Bieler LP owned 0.83% of Charles River Laboratories International worth $78,781,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Virtu Financial LLC bought a new position in Charles River Laboratories International during the third quarter valued at about $601,000. JPMorgan Chase & Co. raised its stake in Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock valued at $95,086,000 after purchasing an additional 85,759 shares in the last quarter. State Street Corp raised its stake in Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock valued at $419,601,000 after purchasing an additional 41,421 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in Charles River Laboratories International by 3.4% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company's stock valued at $22,060,000 after purchasing an additional 3,714 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in Charles River Laboratories International by 7.6% in the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company's stock valued at $9,064,000 after purchasing an additional 3,268 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Analyst Ratings Changes

CRL has been the topic of several recent analyst reports. Robert W. Baird cut their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. Bank of America lowered their price target on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research report on Friday, December 13th. Redburn Atlantic upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target for the company in a research note on Monday, March 3rd. TD Cowen increased their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a report on Monday, November 11th. Finally, Morgan Stanley cut their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $198.36.

Remove Ads

Charles River Laboratories International Price Performance

CRL opened at $175.13 on Tuesday. The stock's 50-day moving average price is $168.99 and its 200 day moving average price is $185.45. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $274.77. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The firm has a market cap of $8.96 billion, a price-to-earnings ratio of 1,167.55, a PEG ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same quarter in the prior year, the business posted $2.46 EPS. The business's revenue for the quarter was down 1.1% on a year-over-year basis. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Birgit Girshick purchased 1,514 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the purchase, the chief operating officer now directly owns 55,058 shares of the company's stock, valued at $9,064,198.54. This represents a 2.83 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. This represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.